Tadashi Terasaka

发表

Discovery of ASP5878: Synthesis and structure-activity relationships of pyrimidine derivatives as pan-FGFRs inhibitors with improved metabolic stability and suppressed hERG channel inhibitory activity.

Ikumi Kuriwaki, M. Kameda, Kazuhiko Iikubo, 2022, Bioorganic & medicinal chemistry.

ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance

Tomoyuki Suzuki, M. Kameda, Tadashi Terasaka, 2017, Cancer science.

Structural basis of compound recognition by adenosine deaminase.

T. Kinoshita, T. Fujii, Tsuyoshi Inoue, 2005, Biochemistry.

Structure-based de novo design of non-nucleoside adenosine deaminase inhibitors.

T. Kinoshita, Tadashi Terasaka, Katsuya Nakamura, 2003, Bioorganic & medicinal chemistry letters.

Discovery of novel and potent CRTH2 antagonists.

Tadashi Terasaka, M. Takeuchi, Y. Imamura, 2012, Bioorganic & medicinal chemistry letters.

Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938.

T. Kinoshita, T. Fujii, Tadashi Terasaka, 2006, European journal of pharmacology.

Inhibition of antigen-induced airway inflammation and hyperresponsiveness in guinea pigs by a selective antagonist of "chemoattractant receptor homologous molecule expressed on Th2 cells" (CRTH2).

Tadashi Terasaka, S. Tsujimoto, Y. Shimizu, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Structure-based design and synthesis of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors.

T. Kinoshita, Tadashi Terasaka, Takeshi Inoue, 2004, Journal of medicinal chemistry.

A Model Compound of the Novel Cofactor Tryptophan Tryptophylquinone of Bacterial Methylamine Dehydrogenases. Synthesis and Physicochemical Properties

S. Fukuzumi, Tadashi Terasaka, K. Kano, 1995 .

Efficient NAD+-recycling system for ADH-catalysed oxidation in organic media

Tadashi Terasaka, S. Itoh, M. Komatsu, 1992 .

Non-nucleoside adenosine deaminase inhibitors: 2000 – 2004

Tadashi Terasaka, 2005 .

ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma

Tomoyuki Suzuki, M. Kameda, Tadashi Terasaka, 2016, Molecular Cancer Therapeutics.

novel inhibitor of FGFR 1 , 2 , 3 , and 4 , inhibits the growth of FGF 19-expressing hepatocellular carcinoma

Tomoyuki Suzuki, M. Kameda, Tadashi Terasaka, 2016 .

Rational design of non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitors: predicting enzyme conformational change and metabolism.

Yasuko Kato, Takayoshi Kinoshita, T. Kinoshita, 2005, Journal of medicinal chemistry.

Synthesis and structure-activity relationships of pyrimidine derivatives as potent and orally active FGFR3 inhibitors with both increased systemic exposure and enhanced in vitro potency.

Ikumi Kuriwaki, M. Kameda, Kazuhiko Iikubo, 2021, Bioorganic & medicinal chemistry.

A highly potent non-nucleoside adenosine deaminase inhibitor: efficient drug discovery by intentional lead hybridization.

Takayoshi Kinoshita, T. Kinoshita, Tadashi Terasaka, 2004, Journal of the American Chemical Society.